New Triple-Threat treatment trial aims to control aggressive bile duct cancer

NCT ID NCT07036380

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a new targeted drug called MP0317 to standard chemotherapy and immunotherapy helps control advanced bile duct cancer better. The trial will include 75 patients who haven't had previous cancer treatments, with 50 receiving the experimental three-drug combination. Researchers will track how long patients live without their cancer getting worse and study how the treatment affects the immune system.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Besançon
RECRUITING

Besançon, France

Contact
CHU de Grenoble
NOT_YET_RECRUITING

Grenoble, France

Contact
CHU de Montpellier
RECRUITING

Montpellier, France

Contact
CHU de Tours
RECRUITING

Tours, France

Contact
Centre Eugène Marquis
NOT_YET_RECRUITING

Rennes, France

Contact
Centre Léon Bérard
NOT_YET_RECRUITING

Lyon, France

Contact
Centre georges-François Leclerc
RECRUITING

Dijon, France

Contact
Hôpital Beaujon
RECRUITING

Paris, France

Contact
Hôpital La Pitié-Salpétrière
NOT_YET_RECRUITING

Paris, France

Contact
Institut Curie
NOT_YET_RECRUITING

Paris, France

Contact
Institut Gustave Roussy
NOT_YET_RECRUITING

Villejuif, France

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED BILIARY TRACT CARCINOMA